Currently, the best studied ALK fusions are NPM1-ALK in anaplastic large-cell lymphoma (ALCL) and EML4-ALK in non-small cell lung cancer (NSCLC), which harbor ALK fusions in approximately 5% of cases [9,10]. This evidence concerns the gene EML4 and non-small cell lung carcinoma.